 |
148 Diseases |  |
56 Trials |
|
56 Trials |  |
3635 News |  |
| «12...7891011121314151617...4041» |
- ||| Januvia (sitagliptin) / Merck (MSD)
Pricing: Another new high. Blood sugar at 173 thanks to @cigna not covering the medication I need to control diabetes. And thanks to @merck for pricing Januvia at $1600 for 90 pills. I could drop dead any moment. Seriously. @DrNickels (Twitter) - Oct 26, 2021
- || Nexavar (sorafenib) / Bayer, Amgen
Review, Journal: Antiangiogenic Drugs in NASH: Evidence of a Possible New Therapeutic Approach. (Pubmed Central) - Oct 25, 2021
The relationship between the worsening of chronic liver disease and angiogenesis may suggest a possible use of drugs with antiangiogenic activity as a tool to stop or slow the progression of the disorder. In this review, we highlight the available preclinical data supporting a role of known antiangiogenic drugs (e.g., sorafenib), or phytotherapeutic compounds with multiple mechanism of actions, including also antiangiogenic activities (e.g., berberine), in the treatment of NASH.
- | Januvia (sitagliptin) / Merck (MSD)
Preclinical, Journal: Long-Term Dipeptidyl Peptidase 4 Inhibition Worsens Hypertension and Renal and Cardiac Abnormalities in Obese Spontaneously Hypertensive Heart Failure Rats. (Pubmed Central) - Oct 22, 2021
Long-term sitagliptin treatment also increased kidney weights, renal vascular resistances, the excretion of kidney injury molecule-1 (indicates injury to proximal tubules), renal interstitial fibrosis, glomerulosclerosis, renal vascular hypertrophy, left ventricular dysfunction, right ventricular degeneration, and the ratios of collagen IV/collagen III and collagen IV/laminin in the right ventricle. Conclusions These findings indicate that, in some genetic backgrounds, long-term DPP4 inhibitor treatment is harmful and identify an animal model to study mechanisms of, and test ways to prevent, DPP4 inhibitor-induced pathological conditions.
- || Januvia (sitagliptin) / Merck (MSD)
Clinical, Journal: A case of dropped head syndrome suspected due to Dipeptidyl peptidase (DPP)-4 inhibitor use (Pubmed Central) - Oct 22, 2021
One month after discontinuation of sitagliptin, MRI findings showed an improvement in the STIR hyperintensity of the posterior cervical muscle. In conclusion, if the initiation of a DPP-4 inhibitor results in dropped head syndrome, discontinuation of the drug should be considered.
- || Rybelsus (semaglutide oral) / Novo Nordisk
Clinical, Review, Journal: Will oral semaglutide be a game-changer in the management of type 2 diabetes in primary care? (Pubmed Central) - Oct 20, 2021
The most common side effects were gastrointestinal, mainly mild-to-moderate and transient nausea. Oral semaglutide may change the paradigm of T2D treatment in primary care.
- ||| Januvia (sitagliptin) / Merck (MSD)
Pricing: $CDXS Codexis, Almelo and RC2 Announce a Tri-Party Collaboration for the Enzymatic Production of Low Cost Sitagliptin API for the Generic Market, Including a License to Codexis Enzyme Technology in India https://t.co/H2JCYKRhXy (Twitter) - Oct 18, 2021
- Januvia (sitagliptin) / Merck (MSD)
[VIRTUAL] DPP4 Inhibitors Ameliorates Endoplasmic Reticulum Stress in Diabetic Kidney Disease Through Upregulation of SIRT1 () - Oct 17, 2021 - Abstract #KIDNEYWEEK2021KIDNEY_WEEK_2033;
Methods In vivo, male DBA2/J mice were injected by streptozotoxin to form diabetic mice models, then sitagliptin(Sita) was gavaged to inhibit DPP4...Our work found that the inhibition of DPP4 ameliorated ER stress in DKD partly through SIRT1/STAT3 signaling pathway. Conclusion The results suggested a novel mechanism links the DPP4 enzyme to ER stress during tubular injury in DKD and highlight that SIRT1/STAT3 pathway may become a potential target for managing DKD.
- Januvia (sitagliptin) / Merck (MSD)
[VIRTUAL] RHABDOMYOLYSIS WITH CONCURRENT ATROVASTATIN AND SITAGLIPTIN IN THE SETTING OF VITAMIN D DEFICIENCY () - Oct 13, 2021 - Abstract #CHEST2021CHEST_1190;
Vitamin D deficiency leading to low levels of available CYP3A4 enzyme and sitagliptin as a competitive inhibitor can all together limit the number of active sites. This can lead to increased statin levels and thus higher chance of myopathy.
- | Invokana (canagliflozin) / J&J, Daiichi Sankyo, Mitsubishi Tanabe, Januvia (sitagliptin) / Merck (MSD)
Journal: The Effects of Canagliflozin compared to Sitagliptin on Cardiorespiratory Fitness in Type 2 Diabetes Mellitus and Heart Failure with Reduced Ejection Fraction: Results of the CANA-HF Study. (Pubmed Central) - Oct 13, 2021
This can lead to increased statin levels and thus higher chance of myopathy. In this small and short-term study of patients with T2DM and HFrEF, interrupted early after only 36 patients, canagliflozin did not improve the primary endpoints of peak VO or VE/VCO slope compared to sitagliptin, while showing favorable trends observed on several additional surrogate endpoints such as lean peak VO , VAT and quality of life.
- || Suglat (ipragliflozin) / EMD Serono, Kotobuki, Astellas, Januvia (sitagliptin) / Merck (MSD)
Clinical, Journal, Combination therapy: Effects of ipragliflozin versus metformin in combination with sitagliptin on bone and muscle in Japanese patients with type 2 diabetes mellitus: Sub-analysis of a prospective, randomized, controlled study (PRIME-V study). (Pubmed Central) - Oct 13, 2021
However, ipragliflozin combination increased the levels of TRACP-5b. A long-term study is required to further understand the effects of this TRACP-5b increase caused by ipragliflozin.
- || Januvia (sitagliptin) / Merck (MSD)
Clinical, Journal: Sitagliptin as an Initial Therapy and Differential Regulations of Metabolic Parameters Depending on its Glycemic Response in Subjects with Type 2 Diabetes. (Pubmed Central) - Oct 13, 2021
3) Good glycemic efficacy of sitagliptin is medicated through reduced insulin resistance as well as enhanced beta-cell functions. Body weight increased, while some atherogenic cholesterol decreased in good-responders.
- | Onglyza (saxagliptin) / AstraZeneca, Januvia (sitagliptin) / Merck (MSD)
Preclinical, Journal, Tumor microenvironment: Antidiabetic DPP-4 Inhibitors Reprogram Tumor Microenvironment That Facilitates Murine Breast Cancer Metastasis Through Interaction With Cancer Cells via a ROS-NF-кB-NLRP3 Axis. (Pubmed Central) - Oct 12, 2021
Thus, our findings suggest that antidiabetic DPP-4i reprograms tumor microenvironment that facilitates murine BC metastasis by interaction with BC cells via a ROS-NRF2-HO-1-NF-κB-NLRP3 axis. This finding not only provides a mechanistic insight into the oncogenic ROS-NRF2-HO-1 in DPP-4i-driven BC progression but also offers novel insights relevant for the improvement of tumor microenvironment to alleviate DPP-4i-induced BC metastasis.
- | Januvia (sitagliptin) / Merck (MSD)
Journal: Repurposing of antidiabetics as Serratia marcescens virulence inhibitors. (Pubmed Central) - Oct 9, 2021
The downregulation of virulence genes was not enough to show anti-virulence activities. Hindering of QS receptors may play a crucial role in diminishing bacterial virulence.
- || Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim, Januvia (sitagliptin) / Merck (MSD)
Clinical, Journal: Rationale and design of the randomised controlled cross-over trial: Cardiovascular effects of empaglifozin in diabetes mellitus. (Pubmed Central) - Oct 8, 2021
This study was retrospectively registered at https://doi.org/10.1186/ISRCTN82391603 and monitored by the University of Leeds. The study results will be submitted for publication within 6 months of completion.
- ||| Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim
Trial completion, HEOR, Cost of care: A Study Based on Data From German Sick Funds That Looks at the Costs of Treatment of Type-2 Diabetic Patients With Empagliflozin vs. DPP-4 Inhibitors vs. GLP-1 Receptor Agonists (clinicaltrials.gov) - Oct 7, 2021
P=N/A, N=24500, Completed, Sponsor: Boehringer Ingelheim
The study results will be submitted for publication within 6 months of completion. Active, not recruiting --> Completed
- || Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim, Januvia (sitagliptin) / Merck (MSD)
Clinical, Journal: A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: the ASSET study. (Pubmed Central) - Oct 7, 2021
Although the effects on cardiac fat and function were not statistically different between the two groups, empagliflozin exhibited superior effects on cardiometabolic biomarkers, such as uric acid, high-density lipoprotein cholesterol, ketone bodies, and insulin sensitivity. Therefore, when considering the primary preventive strategies for CVD, early supplementation with SGLT2 inhibitors may be more beneficial than DPP-4 inhibitors, even in patients with early-stage T2DM without current CVD complications.
- | Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly, Januvia (sitagliptin) / Merck (MSD)
Journal: Dipeptidyl peptidase 4 inhibitor-associated mucous membrane pemphigoid. (Pubmed Central) - Oct 7, 2021
This case suggests that the DPP-4i may have shared roles in the production of IgG antibodies to LAD-1 or to LABD97 in the pathogenesis of DPP-4i-associated BP and MMP. Our case highlights the possibility of overlooking the mild MMP in DPP-4i-treated diabetes patients with mucosal lesions.
- | Januvia (sitagliptin) / Merck (MSD)
Preclinical, Journal: DPP4 inhibitor reduces portal hypertension in cirrhotic rats by normalizing arterial hypocontractility. (Pubmed Central) - Oct 7, 2021
DPP4 inhibition by sitagliptin in vivo has beneficial effects on portal hypertension in cirrhotic rats through normalizing arterial hypocontractility. DDP4 inhibitor may be a novel strategy in the treatment of patients with cirrhosis and portal hypertension.
- | Victoza (liraglutide) / Novo Nordisk, avexitide (exendin 9-39) / Eiger, Januvia (sitagliptin) / Merck (MSD)
Trial completion, Enrollment change: Cardiovascular Effects of GLP-1 Receptor Activation (clinicaltrials.gov) - Oct 6, 2021
P4, N=88, Completed, Sponsor: Vanderbilt University Medical Center
DDP4 inhibitor may be a novel strategy in the treatment of patients with cirrhosis and portal hypertension. Recruiting --> Completed | N=160 --> 88
- ||| Januvia (sitagliptin) / Merck (MSD)
@signestensen identifies the role of GIP as a target for sitagliptin action in PPL #T2D #EASD2021 @EASDnews (Twitter) - Sep 30, 2021
- | Retrospective data, Review, Journal: Cardiovascular events and all-cause mortality in patients with type 2 diabetes treated with dipeptidyl peptidase-4 inhibitors: An extensive meta-analysis of randomized controlled trials. (Pubmed Central) - Sep 29, 2021
As a class, DPP4i are not associated with any increase or reduction of MACE, all-cause mortality, and heart failure. Saxagliptin seems to be associated with an increased risk of hospitalization for heart failure.
- |||||| prusogliptin (DBPR108) / CSPC Pharma
Enrollment open: A Study to Evaluate the Efficacy and Safety of DBPR108 100 mg in Type 2 Diabetes Mellitus Patients (clinicaltrials.gov) - Sep 28, 2021
P3, N=750, Recruiting, Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Saxagliptin seems to be associated with an increased risk of hospitalization for heart failure. Not yet recruiting --> Recruiting
- | Januvia (sitagliptin) / Merck (MSD)
Trial completion date, Trial primary completion date: SIDIACO: The Effect of Sitagliptin Treatment in COVID-19 Positive Diabetic Patients (clinicaltrials.gov) - Sep 28, 2021
P3, N=170, Not yet recruiting, Sponsor: University of Milan
Not yet recruiting --> Recruiting Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Mar 2021 --> Mar 2022
- || Rybelsus (semaglutide oral) / Novo Nordisk
Clinical, Journal: Efficacy of oral semaglutide: overview of the PIONEER clinical trial program and implications for managed care. (Pubmed Central) - Sep 26, 2021
Oral semaglutide was also efficacious in patients with T2D and moderate renal impairment. These findings indicate that oral semaglutide presents a valuable option for treating patients with T2D in a managed care setting, with the potential to expand the number of patients benefiting from GLP‑1RAs.
- || Rybelsus (semaglutide oral) / Novo Nordisk
Clinical, Journal, Patient reported outcomes: The importance of patient-reported outcomes in type 2 diabetes: insight from the PIONEER program with oral semaglutide. (Pubmed Central) - Sep 26, 2021
Significant improvements in craving control and craving for savory were observed with oral semaglutide versus empagliflozin in the Control of Eating Questionnaire (in PIONEER 2). These data provide valuable information that can facilitate a patient-centered approach and guide decision-making in managed care to optimize each patient's treatment experience.
- Rybelsus (semaglutide oral) / Novo Nordisk, Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim, Januvia (sitagliptin) / Merck (MSD)
[VIRTUAL] Provider Evaluation for Selection of Evidence-Based Therapies to Reduce Cardiovascular Complications in Patients With Type 2 Diabetes Mellitus Study - Primary Results of the PREFER-DM Study (OnDemand) - Sep 24, 2021 - Abstract #AHA2021AHA_5958;
HCPs across specialities prefer oral antihyperglycemic drug attributes associated with CV risk reduction over side effect profile, tolerability, and adverse outcomes. Whether these preferences translate to prescription patterns and patient acceptance of oral antihyperglycemic drugs in clinical settings remains to be investigated.
- [VIRTUAL] A Real-World Disproportionality Analysis of Atrial Fibrillation Adverse Events for Glucagon Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors (OnDemand) - Sep 24, 2021 - Abstract #AHA2021AHA_5940;
This complements the existing evidence and alludes to the protective role of GLP-1 RA against AF. In contrast, the reporting frequency of AF was significantly higher in DPP-4i group, especially with saxagliptin and linagliptin.
- Byetta (exenatide) / AstraZeneca, Januvia (sitagliptin) / Merck (MSD)
[VIRTUAL] Mitochondrial Metabolites Predict Cardiovascular Outcomes and Heart Failure in Individuals with Type 2 Diabetes Mellitus: An Exscel Biomarker Substudy (ePosters) - Sep 24, 2021 - Abstract #AHA2021AHA_2912;
Metabolites reporting on dysregulated mitochondrial fatty acid oxidation are increased in individuals with T2D who experience MACE. These biomarkers may improve CV risk prediction models, appear to be beneficially modified by exenatide, and highlight emerging risk mechanisms.
- Januvia (sitagliptin) / Merck (MSD)
[VIRTUAL] A case of severe bullous pemphigoid associated with the use of dipeptidyl peptidase-4 inhibitor sitagliptin () - Sep 24, 2021 - Abstract #EADV2021EADV_1505;
- || Januvia (sitagliptin) / Merck (MSD)
Clinical, Journal: Islet function and insulin sensitivity in latent autoimmune diabetes in adults taking sitagliptin: A randomized trial. (Pubmed Central) - Sep 23, 2021
These biomarkers may improve CV risk prediction models, appear to be beneficially modified by exenatide, and highlight emerging risk mechanisms. Compared with insulin intervention alone, sitagliptin plus insulin treatment appeared to maintain β-cell function and improve insulin sensitivity in LADA to some extent.
- | Rybelsus (semaglutide oral) / Novo Nordisk
Journal, HEOR: Cost-effectiveness of oral semaglutide added to current antihyperglycemic treatment for type 2 diabetes. (Pubmed Central) - Sep 22, 2021
Guzauskas and Hansen have nothing to disclose. Study results were presented at the New England Comparative Effectiveness Public Advisory Council (New England CEPAC), November 14, 2019, at Brown University, Providence, RI.
- | Januvia (sitagliptin) / Merck (MSD)
Preclinical, Journal: Dipeptedyl peptidase-4 (DPP-4) inhibitor downregulates HMGB1/TLR4/NF-κB signaling pathway in a diabetic rat model of non-alcoholic fatty liver disease. (Pubmed Central) - Sep 21, 2021
An ameliorative action of Sitagliptin in NAFLD was demonstrated via decreasing HMGB1-mediated TLR4/NF-κB signalling in order to suppress inflammation and reduce insulin resistance. Sitagliptin may in fact prove to be a beneficial therapeutic intervention in NAFLD.
- | Januvia (sitagliptin) / Merck (MSD)
Preclinical, Journal: Oral anti-diabetic drugs as endocrine disruptors in vitro - No evidence for additive effects in binary mixtures. (Pubmed Central) - Sep 19, 2021
The complexity of dynamic pathways such as steroidogenesis appears to significantly reduce the use of the CA model. In conclusion, more dynamic models are needed to predict mixture effects in complex systems.
- || Rybelsus (semaglutide oral) / Novo Nordisk, Januvia (sitagliptin) / Merck (MSD)
Clinical, Journal, HEOR: Budget Impact of Oral Semaglutide Intensification versus Sitagliptin among US Patients with Type 2 Diabetes Mellitus Uncontrolled with Metformin. (Pubmed Central) - Sep 19, 2021
In conclusion, more dynamic models are needed to predict mixture effects in complex systems. Use of oral semaglutide 14 mg in patients currently receiving sitagliptin 100 mg substantially increases the budget impact for patients with T2DM whose blood glucose level is not controlled with metformin over a 5-year time horizon for US healthcare payers.
- || Rybelsus (semaglutide oral) / Novo Nordisk
Review, Journal: Advances in GLP-1 treatment: focus on oral semaglutide. (Pubmed Central) - Sep 18, 2021
Oral semaglutide broadens therapy options and facilitates the adoption of earlier GLP-1 RA treatment once T2D patients present low rates of treatment discontinuation. The main adverse events reported were related to the gastrointestinal tract, common to GLP-1 RA class drugs.
- | Januvia (sitagliptin) / Merck (MSD)
Journal: Sitagliptin Reduces Endothelial Dysfunction and Apoptosis Induced by High-Fat Diet and Palmitate in Thoracic Aortas and Endothelial Cells via ROS-ER Stress-CHOP Pathway. (Pubmed Central) - Sep 18, 2021
SIT treatment obviously ameliorated apoptosis via alleviating ROS and ER stress in the thoracic aortas isolated from HFD-fed rats and PA-treated HUVECs. The results suggest that SIT improved endothelial function via promoting cell proliferation and alleviating ROS-ER stress-CHOP pathway both in vivo and in vitro.
- | Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca, Januvia (sitagliptin) / Merck (MSD)
Journal: Development and optimization of sitagliptin and dapagliflozin loaded oral self-nanoemulsifying formulation against type 2 diabetes mellitus. (Pubmed Central) - Sep 17, 2021
The anti-diabetic studies showed the significant inhibition of glucose level in treated diabetic mice by SNEDDS combined dose compared to the single drug therapy. The combined dose of sitagliptin-dapagliflozin using SNEDDS could be a potential oral pharmaceutical product for the improved treatment of type 2 diabetes mellitus.
- | Januvia (sitagliptin) / Merck (MSD)
Preclinical, Journal: Alleviation of diabetes mellitus through the restoration of β-cell function and lipid metabolism by Aloe vera (L.) Burm. f. extract in Obesogenic WNIN/GR-Ob rats. (Pubmed Central) - Sep 16, 2021
Thus, it has great therapeutic potential as an herbal remedy for the treatment of diabetes and associated adverse effects such as obesity. The exact mechanism underlying the observation needs to be investigated further to explore the anti-obesity and anti-diabetic properties of A. vera and advocate its potential application as alternative medicine.
- | Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca, Januvia (sitagliptin) / Merck (MSD)
New trial: Dapa-LiT: Effect of Dapagliflozin vs Sitagliptin on Liver Fat Accumulation and Body Composition in Patients With Diabetes Mellitus and Liver Transplantation (clinicaltrials.gov) - Sep 12, 2021
P=N/A, N=100, Not yet recruiting, Sponsor: Medanta, The Medicity, India
- | Januvia (sitagliptin) / Merck (MSD)
Preclinical, Journal: Dipeptidyl peptidase-4 (DPP4) inhibitor sitagliptin alleviates liver inflammation of diabetic mice by acting as a ROS scavenger and inhibiting the NFκB pathway. (Pubmed Central) - Sep 9, 2021
Moreover, sitagliptin reduced TNFα or LPS-induced cellular reactive oxygen species (ROS) level, cell apoptosis, and protein expression in the NFκB signaling pathway in HepG2 cells or primary mouse hepatocytes. Altogether, our study confirms that sitagliptin may protect liver tissue by alleviating ROS production and NFκB signaling activation, providing a putative mechanism for preventing the development of diabetic liver disease.
- || Januvia (sitagliptin) / Merck (MSD)
$CDXS Codexis and Merck Amend and Extend Supply Agreement for Enzyme Used in Manufacture of Sitagliptin https://t.co/ictZHfZp5W (Twitter) - Sep 9, 2021
- Januvia (sitagliptin) / Merck (MSD)
Duodenitis Leading to Diagnosis of Sarcoidosis (Shoreline Exhibit Hall) - Sep 8, 2021 - Abstract #ACG2021ACG_2374;
Patient presents with a 36 lb weight loss; recently she independently discontinued Sitagliptin and recovered from URTI...Although the EGD revealed normal duodenal mucosa, small bowel involvement may be missed on superficial biopsies given the submucosal location of granulomatous inflammation. Our patient will commence standard first-line glucocorticoid treatment.Figure: Contrasted CT of the abdomen demonstrating focal duodenitis without mass.
- || Januvia (sitagliptin) / Merck (MSD)
Clinical, Journal: Effect of sitagliptin on proteinuria in patients with type 2 diabetes - A renoprotective effect of sitagliptin. (Pubmed Central) - Sep 7, 2021
Univariate analysis showed that changes in ACR correlated with FBS (r = 0.68, P < 0.0001), insulin (r = 0.44, P = 0.03), and homeostatic model assessment for insulin resistance (r = 0.69, P < 0.0001) and did not correlate with eGFR and BP. In conclusion, sitagliptin is a well-tolerated drug that improves glycemic control, lowers BP, and reduces urinary albumin excretion, especially in Ma type 2 diabetic patients.
- | Januvia (sitagliptin) / Merck (MSD)
Preclinical, Journal: Synergistic effects of sitagliptin and losartan against fipronil-induced hepatotoxicity in rats. (Pubmed Central) - Sep 4, 2021
The administration of Sit and LOS before and alongside FPN markedly mitigated the alterations caused by FPN and the hepatoprotective effects were more prominent in the combination group. Sit and LOS, both individually or in combination, confers considerable hepatoprotection against FPN-induced hepatotoxicity.
- || Januvia (sitagliptin) / Merck (MSD)
Clinical, Journal, Real-world evidence: Sodium-Glucose Cotransporter-2 Inhibitor Use is Associated with a Reduced Risk of Heart Failure Hospitalization in Patients with Heart Failure with Preserved Ejection Fraction and Type 2 Diabetes Mellitus: A Real-World Study on a Diverse Urban Population. (Pubmed Central) - Sep 4, 2021
Sit and LOS, both individually or in combination, confers considerable hepatoprotection against FPN-induced hepatotoxicity. The use of SGLT2is is associated with a reduced incidence of HFH and AKI in patients with HFpEF and T2DM.
- || Januvia (sitagliptin) / Merck (MSD)
Clinical, Journal: Evaluation of Interleukin-23 and JAKs/STATs/SOCSs/ROR-γt Expression in Type 2 Diabetes Mellitus Patients Treated With or Without Sitagliptin. (Pubmed Central) - Sep 4, 2021
Enhanced IL-23/JAK2/STAT3/ROR-γt and reduced SOCS1/SOCS3 were found in SN patients. Sitagliptin may regulate the IL-23 and related gene expression.
- || Onglyza (saxagliptin) / AstraZeneca, Januvia (sitagliptin) / Merck (MSD)
Clinical, Journal: Effect of dipeptidyl peptidase IV inhibitors, thiazolidinedione, and sulfonylurea on osteoporosis in patients with type 2 diabetes: population-based cohort study. (Pubmed Central) - Aug 29, 2021
Sitagliptin may regulate the IL-23 and related gene expression. DPP-IV inhibitors do not increase the risk of osteoporosis compared with sulfonylureas in patients with type 2 diabetes mellitus, while a weak association was found between thiazolidinediones and increased risk of osteoporosis.
- | Januvia (sitagliptin) / Merck (MSD)
Preclinical, Journal: Sitagliptin Modulates Oxidative, Nitrative and Halogenative Stress and Inflammatory Response in Rat Model of Hepatic Ischemia-Reperfusion. (Pubmed Central) - Aug 28, 2021
As compared to IR, the SIR animals had a lower expression of interleukin-6 (by 4.2-fold) and midkine (by 2-fold), a lower concentration of 3-nitrotyrosine (by 2.5-fold) and a higher Nox4 (by 2.9-fold) and 3-bromotyrosine (by 1.4-fold). In conclusion, IR disturbs the oxidative, nitrative and halogenative balance and aggravates the inflammatory response in the liver, which can be attenuated by low doses of sitagliptin.
- | Januvia (sitagliptin) / Merck (MSD)
Journal, IO biomarker: Sitagliptin attenuates endothelial dysfunction independent of its blood glucose controlling effect. (Pubmed Central) - Aug 28, 2021
Sitagliptin attenuates injuries of vascular endothelial cells caused by high glucose through inhibiting over-activated autophagy. JNK-Bcl-2-Beclin-1 pathway may be involved in this process.
- || Clinical, Reimbursement, Journal, Medicare: Potentially Inappropriately Prescribed Medications Among Medicare Medication Therapy Management Eligible Patients with Chronic Kidney Disease: an Observational Analysis. (Pubmed Central) - Aug 27, 2021
Majority of PIPMs were prescribed by PCPs. Clinical decision support tools may be considered to potentially reduce PIPM among Medicare MTM-enrolled patients with CKD.